RA Capital Nexus Fund II, L.P.
CIK 1825376 · last filed 2026-06-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$94.05M
Companies
10
Total Filings
17
Lifetime Open-Market Net
$697.31M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PEPG | Director | — | $1.83 | — | $0 | 2 | 2026-06-22 |
| LENZ | Director | — | $5.88 | — | $0 | 2 | 2026-06-15 |
| JANX | Director | 1,048,406 | $15.00 | $15.73M | $0 | 4 | 2025-06-13 |
| Climb Bio, Inc. (ELYM) Delisted | Director | 841,087 | $5.11 | $4.30M | $349.67M | 1 | 2024-07-01 |
| HOWL | Director | — | $0.45 | — | $0 | 1 | 2024-05-24 |
| ACRV | Director | 7,914,206 | $1.54 | $12.19M | $0 | 1 | 2024-04-15 |
| Icosavax, Inc. (ICVX) Delisted | Director | 0 | $15.31 | $0 | $4.18M | 2 | 2024-02-20 |
| SPRY | Director | 8,556,774 | $5.67 | $48.52M | $40.92M | 1 | 2023-09-25 |
| DICE Therapeutics, Inc. (DICE) Delisted | Director | 6,848,911 | $47.55 | $325.67M | $299.30M | 1 | 2022-10-19 |
| ANTX | 10%+ Owner | 3,748,087 | $4.70 | $17.62M | $3.24M | 1 | 2022-06-15 |
Recent Filings · Page 2 of 2
17 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-03-06 | JANX | Buy (P) | — | $0 | EDGAR |
| 2024-02-20 | Icosavax, Inc. (ICVX) Delisted | Mixed | −29,845,540 | $0 | EDGAR |
| 2023-09-25 | SPRY | Buy (P) | +13,500,000 | $40.92M | EDGAR |
| 2023-06-16 | JANX | Grant (A) | — | $0 | EDGAR |
| 2022-10-19 | DICE Therapeutics, Inc. (DICE) Delisted | Buy (P) | +8,200,000 | $299.30M | EDGAR |
| 2022-06-15 | ANTX | Buy (P) | +407,120 | $3.24M | EDGAR |
| 2022-03-30 | Icosavax, Inc. (ICVX) Delisted | Buy (P) | +921,090 | $4.18M | EDGAR |
Showing 11–17 of 17
Prev
Page 2 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.